Clinical Trials on Psoriasis Vulgaris

Total 2853 results

University of Alabama at Birmingham
Celgene

Completed

An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis

Psoriasis | Psoriasis Vulgaris | Psoriatic Nail

United States
Centre of Evidence of the French Society of Dermatology

Recruiting

Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines

Psoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis Pustular

France
Novartis Pharmaceuticals

Active, not recruiting

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

Psoriasis Vulgaris | Pustular Psoriasis | Psoriatic Arthritis

Japan
ProgenaBiome

Recruiting

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

Psoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis Geographica

United States
Radboud University Medical Center
Sint Maartenskliniek

Completed

Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER)

Psoriasis | Psoriasis Vulgaris | Psoriatic Arthritis | Psoriatic Nail

Netherlands
Kyowa Kirin Co., Ltd.

Completed

A Phase 3 Clinical Study of KHK 4827

Psoriasis Vulgaris | Psoriatic Arthritis | Pustular; Psoriasis, Palmaris Et Plantaris | Psoriatic Erythroderma

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 4 Clinical Study of Brodalumab

Psoriasis Vulgaris | Psoriatic Arthritis | Pustular; Psoriasis, Palmaris Et Plantaris | Psoriatic Erythroderma

Japan
Pfizer

Completed

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)

Psoriasis Vulgaris | Pustular Psoriasis | Psoriasis Arthropathica | Erythrodermic Psoriasis

Japan
Innovaderm Research Inc.
Ciusss de L'Est de l'Île de Montréal

Withdrawn

Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

Psoriasis Vulgaris | Active Psoriatic Arthritis
University of Southern California

Completed

Impact of Decision-Framing in Psoriasis

Psoriasis | Psoriasis Vulgaris | Psoriatic Arthritis

United States
selectION Therapeutics GmbH
FGK Clinical Research GmbH

Recruiting

A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis

Psoriasis Vulgaris | Psoriatic Arthritis

Germany
LEO Pharma

Completed

Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation

Plaque Psoriasis | Psoriasis Vulgaris

Germany
Soligenix

Recruiting

Topical SGX302 for Mild-to-Moderate Psoriasis

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

United States
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (COBRA)

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

Belgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
PRCL Research Inc.

Completed

A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis | Psoriasis Vulgaris

Canada, Slovakia, Ukraine
Chinese University of Hong Kong

Not yet recruiting

Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis

Psoriasis Vulgaris
University Hospital, Ghent

Recruiting

Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS) (BIOLOPTIM-RIS)

Psoriasis Vulgaris

Belgium
University Hospital, Ghent

Recruiting

Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients (BIOLOPTIM-TIL)

Psoriasis Vulgaris

Belgium
University of California, San Francisco
Novartis Pharmaceuticals; National Psoriasis Foundation

Recruiting

Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis (DREAMS-PSO)

Psoriasis Vulgaris

United States
University of California, San Francisco
Sun Pharmaceutical Industries Limited

Recruiting

Predicting Inflammatory Skin Disease Response to IL-23 Blockade

Psoriasis Vulgaris

United States
Centre for Human Drug Research, Netherlands
Janssen Pharmaceuticals

Recruiting

An Explorative Psoriasis Biomarker Study

Psoriasis Vulgaris

Netherlands
University Hospital, Ghent
KU Leuven; University Ghent

Recruiting

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO) (BIOLOPTIM-BRO)

Psoriasis Vulgaris

Belgium
University of California, San Francisco
National Psoriasis Foundation

Recruiting

Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris

Psoriasis | Psoriasis Vulgaris

United States
University Hospital, Ghent
KU Leuven; University Ghent

Completed

Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients (BIOLOPTIM-GUS)

Psoriasis Vulgaris

Belgium
University Hospital, Ghent
KU Leuven; University Ghent

Completed

Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients (BIOLOPTIM-IXE)

Psoriasis Vulgaris

Belgium
Lipidor AB
Bioskin GmbH

Completed

Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis (AKVANO-AKP01)

Psoriasis Vulgaris

Germany
Narrows Institute for Biomedical Research
Novartis

Unknown

Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).

Psoriasis Vulgaris

United States
National Medical Research Center for Children's...

Completed

Informative Value of Determining the Level of NF-κB Translocation in Lymphocyte Populations in Children With Psoriasis

Psoriasis Vulgaris

Russian Federation
Wake Forest University Health Sciences

Withdrawn

Iontophoresis in Psoriasis

Skin Diseases | Psoriasis | Psoriasis Vulgaris

United States
Assiut University

Completed

Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis

Psoriasis Vulgaris

Egypt
MC2 Therapeutics

Completed

A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream

Psoriasis Vulgaris

United States
Chang Gung Memorial Hospital
National Science Council, Taiwan

Completed

Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment

Psoriasis Vulgaris

Taiwan
LEO Pharma

Completed

A Vasoconstriction Study With LEO 90100

Psoriasis Vulgaris

France
LEO Pharma

Completed

Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100

Psoriasis Vulgaris

France
Assiut University

Unknown

Combined Oral Vitamin D and UVB Versus UVB Alone in Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris
LEO Pharma

Completed

An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects

Psoriasis Vulgaris

United States, Canada, United Kingdom, Germany, Romania, France, Poland
Assiut University

Unknown

Serum Granulysin Level as a Marker to Detect the Severity of Psoriasis

Psoriasis Vulgaris

Egypt
Postgraduate Institute of Medical Education and...

Unknown

Comparison of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis

Psoriasis Vulgaris
LEO Pharma

Completed

Vasoconstriction Trial With LEO 90100 Aerosol Foam

Psoriasis Vulgaris

France
LEO Pharma

Completed

LEO 32731 - A Phase I Study in Healthy Subjects

Psoriasis Vulgaris

United Kingdom
Galderma R&D

Completed

Safety and Efficacy of CD10367 in Psoriasis Vulgaris

Psoriasis Vulgaris

France
Prof. Kristian Reich

Completed

Trial in Patients With Psoriasis Treated With Methotrexate Using an Optimized Treatment Schedule (METOP) (METOP)

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects

Psoriasis Vulgaris

United Kingdom
Pfizer

Completed

A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis

Psoriasis Vulgaris

Germany
University of Minnesota
Allergan

Completed

Use of Botulinum Toxin to Treat Psoriasis

Psoriasis Vulgaris

United States
LEO Pharma

Completed

The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris

Psoriasis Vulgaris

Belgium, Canada, France, Germany, Netherlands, Spain, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris

Psoriasis Vulgaris

Ireland, Germany, United Kingdom, Canada, Sweden

Clinical Trials on Psoriasis Vulgaris

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations